NCT07169942 - Aleniglipron Phase 2 Body Composition Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

October 31, 2026

Conditions

Obesity, Overweight, or Chronic Weight Management

Interventions

DRUG

aleniglipron or placebo

Drug: aleniglipron administered orally Drug: placebo administered orally

Trial Locations (11)

14609

RECRUITING

Research Site, Rochester

28401

RECRUITING

Research Site, Wilmington

29405

RECRUITING

Research Site, North Charleston

29461

RECRUITING

Research Site, Moncks Corner

55423

RECRUITING

Research Site, Richfield

60602

RECRUITING

Research Site, Chicago

63303

RECRUITING

Research Site, City of Saint Peters

73069

RECRUITING

Research Site, Norman

78240

RECRUITING

Research Site, San Antonio

78704

RECRUITING

Research Site, Austin

85020

RECRUITING

Research Site, Phoenix

All Listed Sponsors

lead

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

INDUSTRY